Tempus, a leader in artificial intelligence and precision medicine, today announced that six abstracts were accepted for presentation at the 2022 San Antonio Breast Cancer Symposium, which convenes from December 6-10, in San Antonio, Texas. Tempus continues to be a leader in advancing breast cancer research, demonstrated in the six abstracts being presented this year.
“Tempus is excited to be returning to SABCS to present abstracts highlighting the impact of our comprehensive genomic data and intelligent diagnostics on clinicians’ ability to deliver personalized treatments for breast cancer patients,” said Calvin Chao, MD, Senior Vice President of Medical Affairs at Tempus.
This year, Tempus is sharing its latest collaborative scientific and clinical research findings via poster presentations. Highlights include:
- Special Poster Presentation Discussion (HER2-08): Molecular characterization of HER-2 low patients identifies basal-enriched subset with poor clinical outcomes in real-world data
- Session Date & Time: Wednesday, December 7, 2022; 9:45 – 11:00 a.m. CT
- Location: Henry B. González Convention Center, Hall 3
- Overview: This study retrospectively analyzed Tempus’ real-world data of patients with HER2-low breast cancer, and found that when HER2-low patients were clustered according to Tempus’ HER2 expression signature identifying three distinct molecular clusters, a distinct cluster of predominately basal-like HER2-low patients had shorter progression-free survival than other HER2-low patients. This data further reveals the potential for RNA expression to fully characterize clinically relevant subpopulations.
- Poster Presentation (P4-05-08): Dual ctDNA and tissue sequencing improves detection of actionable variants in patients with breast cancer
- Session Date & Time: Thursday, December 8, 2022; 5:00 – 6:15 p.m. CT
- Location: Henry B. González Convention Center, Hall 1
- Overview: In this study of metastatic breast cancer patients sequenced concurrently with liquid- and tissue-based next-generation sequencing tests, it was found that 20% of patients had unique gene alteration findings identified in liquid alone that would have been missed by tumor tissue testing. This study suggests that dual testing in patients with breast cancer improves the identification of clinically actionable variants that may be missed by either ctDNA or tissue biopsy alone.
To learn more, visit https://tempus.co/3VlyD3W.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make near real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.